natgillin/translations-raw huggingface dataset:
The study included patients with renal impairment classified on the basis of creatinine clearance (based on the Cockcroft-Gault formula) as mild (> 50 to ≤ 80 ml/min), moderate (≥ 30 to ≤ 50 ml/min), or severe (< 30 ml/min), as well as patients with ESRD on haemodialysis.
Študija je zajela bolnike, pri katerih so okvaro ledvic na podlagi očistka kreatinina (izračunanega po Cockcroft-Gaultovi formuli) razvrstili kot blago (>50 do ≤80 ml/min), zmerno (≥30 do ≤50 ml/min) ali hudo (<30 ml/min), kot tudi bolnike s končno odpovedjo ledvic na hemodializi.
The study included patients with renal impairment classified on the basis of creatinine clearance as mild (50 to < 80 ml/min), moderate (30 to < 50 ml/min), and severe (< 30 ml/min), as well as patients with end-stage renal disease (ESRD) on haemodialysis.
V študiji so sodelovali bolniki z ledvično okvaro, ki je bila na podlagi kreatininskega očistka ocenjena kot blaga (50 do < 80 ml/min), zmerna (30 do < 50 ml/min) ali huda (< 30 ml/min), in bolniki s končno ledvično odpovedjo na hemodializi.
The study included three treatment arms and was designed to compare each of the palifermin arms (pre- and pre/post-) to placebo.
Študija je vključevala 3 terapevtske skupine, njen namen pa je bil primerjati vsako od skupin, ki sta prejemali palifermin (pred in pred/po), s placebom.
The study investigated the efficacy and safety of two different degarelix monthly dosing regimens with a starting dose of 240 mg (40 mg/ml) followed by monthly doses subcutaneous administration of 160 mg (40 mg/ml) or 80 mg (20 mg/ml), in comparison to monthly intramuscular administration of 7.5 mg leuprorelin in patients with prostate cancer requiring androgen deprivation therapy.
V študiji so raziskovali učinkovitost in varnost dveh različnih shem mesečnega odmerjanja degareliksa z začetnim odmerkom 240 mg (40 mg/ml), ki so mu sledili subkutano dani vsakomesečni odmerki po 160 mg (40 mg/ml) ali 80 mg (20 mg/ml), v primerjavi z vsakomesečnim intramuskularnim dajanjem levprorelina v odmerku 7,5 mg pri bolnikih z rakom prostate, zaradi katerega je bilo potrebno zdravljenje z deprivacijo androgenov.
The study involved 343 patients with ALK-positive NSCLC and compared Xalkori with other cancer medicines (pemetrexed with either cisplatin or carboplatin).
Študija je zajela 343 bolnikov z ALK-pozitivnim nedrobnoceličnim pljučnim rakom, v njej pa so zdravilo Xalkori primerjali z drugimi zdravili za zdravljenje raka (pemetreksedom v kombinaciji bodisi s cisplatinom ali karboplatinom).
The study involved 347 patients with ALK-positive NSCLC and compared Xalkori with 1 of 2 cancer medicines (either pemetrexed or docetaxel).
Študija je zajela 347 bolnikov z ALK-pozitivnim nedrobnoceličnim pljučnim rakom, v njej pa so zdravilo Xalkori primerjali z enim od dveh zdravil za zdravljenje raka (pemetreksedom ali docetakselom).
The study involved 39 patients over 6 years of age and compared Kalydeco with placebo.
Vanjo je bilo vključenih 39 bolnikov, starejših od šest let, v njej pa so zdravilo Kalydeco primerjali s placebom.
The study involved 392 adult patients with differentiated thyroid carcinoma that had shown signs of progression in the previous year and did not respond to treatment with radioactive iodine.
V njej je sodelovalo 392 odraslih bolnikov z diferenciranim karcinomom ščitnice, ki so v preteklem letu kazali znake napredovanja in se niso odzivali na zdravljenje z radioaktivnim jodom.
The study involved over 2,000 adults with cancer who were receiving their first course of chemotherapy including cisplatin.
V študiji je sodelovalo 2 000 odraslih, obolelih za rakom, ki so prejemali prvi cikel kemoterapije, ki je vključevala cisplatin.
The study lasted 12 months, and measured the children’s height at the beginning and the end of the study, and the speed of growth during the study.
V raziskavi, ki je trajala 12 mesecev, so merili višino otrok na začetku in koncu raziskave ter hitrost rasti med raziskavo.
The study lasted nine months, and measured the height at the beginning and the end of the study, and the speed of growth during the study.
Študija je trajala 9 mesecev, v njenem okviru pa so merili višino na začetku in koncu študije ter hitrost rasti med študijo.
The study looked at bodyweight and the amount of chloride in sweat, both of which are reduced in patients with cystic fibrosis.
V študiji so opazovali telesno maso in količino klorida v znoju, saj sta obe nižji pri bolnikih s cistično fibrozo.
The study looked at sensitivity and specificity of the PET scans (how well they identified volunteers with plaques in the brain and how accurate they were in distinguishing them from those who did not).
V študiji so proučevali občutljivost in specifičnost PET- preiskav (kako dobro so odkrile prostovoljce z lehami v možganih in s kakšno natančnostjo so jih ločile od tistih, ki jih niso imeli).
The study looked at the ability of the medicine to prevent the progression of disability over three years.
V študiji so ugotavljali sposobnost zdravila za preprečevanje napredovanja prizadetosti v triletnem obdobju.
The study looked at the duration of severe neutropenia during the patients’ first cycle of cytotoxic chemotherapy.
Študija je preučevala trajanje hude nevtropenije med prvim ciklom citotoksične kemoterapije, ki ga je prejel bolnik.
The study looked at the duration of severe neutropenia during the patients’ first cycle of cytotoxic chemotherapy.
Študija je proučevala trajanje hude nevtropenije med prvim ciklom citotoksične kemoterapije, ki ga je prejel bolnik.
The study looked at the levels of cortisol in the patients’ blood during a 24 hour period following three months of treatment.
V študiji so merili raven kortizola v krvi bolnikov v 24-urnem obdobju po treh mesecih zdravljenja.
The study looked at the safety and effectiveness of Aptivus, and at the levels of the medicine in the patients’ blood.
V študiji so proučevali varnost in učinkovitost zdravila Aptivus ter ravni zdravila v bolnikovi krvi.
The study looking at the rapid vaccination course found that a 7-day accelerated vaccination course did not produce lower protection than the standard 4-week vaccination course.
V študiji, s katero so proučevali hitro shemo cepljenja, so ugotovili, da zaščitna raven po sedemdnevnem hitrem postopku ni bila nižja kot po običajnem štiritedenskem postopku.
The study measured the number of children who developed an S. pneumoniae invasive disease during the 3.5 years of the study.
V študiji so preverjali število otrok, pri katerih se je v 3,5- letnem obdobju te študije pojavila invazivna bolezen zaradi bakterije S. pneumoniae.
The study measured the time it took for a patient to develop clinically defined MS.
V študiji so merili čas, v katerem se je pri bolniku razvila klinično dokončna multipla skleroza.
The study measured the time it took for a patient to develop clinically defined MS.
V študiji so merili, v kolikem času se je pri bolniku razvila klinično dokončna multipla skleroza.
The study met its primary endpoint and showed a statistically significant improvement in PFS in the pemetrexed arm over the placebo arm (N = 472, independently reviewed population; median of 3.9 months and 2.6 months, respectively) (hazard ratio = 0.64, 95% CI = 0.51-0.81, p = 0.0002).
Študija je dosegla svoj primarni ciljni učinek in dokazala statistično pomembno izboljšanje preživetja brez napredovanja bolezni v skupini, ki je prejemala pemetreksed, v primerjavi s skupino, ki je prejemala placebo (n = 472, neodvisno pregledana populacija; mediano 3,9 meseca in 2,6 meseca) (razmerje tveganja = 0,64, 95 % CI = 0,51-0,81, p = 0,0002).
The study met its primary endpoint and showed a statistically significant improvement in PFS in the pemetrexed arm over the placebo arm (n = 472, independently reviewed population; median of 3.9 months and 2.6 months, respectively) (hazard ratio = 0.64, 95% CI = 0.51-0.81, p = 0.0002).
Študija je dosegla svoj primarni ciljni učinek in dokazala statistično pomembno izboljšanje preživetja brez napredovanja bolezni v veji, ki je prejemala pemetreksed, v primerjavi z vejo, ki je prejemala placebo (n = 472, neodvisno pregledana populacija; mediano 3,9 meseca in 2,6 meseca) (razmerje tveganja = 0,64, 95 % IZ = 0,51-0,81, p = 0,0002).
The study met its primary endpoint and showed a statistically significant improvement in PFS in the pemetrexed arm over the placebo arm (N = 581, independently reviewed population; median of 4.0 months and 2.0 months, respectively) (hazard ratio = 0.60,95% CI = 0.49-0.73, p < 0.00001).
Študija je dosegla svojo primarno končno točko in pokazala statistično značilno izboljšanje preživetja brez napredovanja v skupini s pemetreksedom glede na skupino s placebom (n = 581, neodvisno pregledana populacija; mediana 4,0 mesece in 2,0 meseca) (razmerje tveganja = 0,60, 95 % CI: 0,49- 0,73, p < 0,00001).
The study met its primary objective of statistically significantly improved PFS for olaparib maintenance monotherapy compared with placebo in the overall population (HR 0.35; 95% CI
Študija je dosegla svoj primarni cilj, statistično značilno izboljšanje preživetja brez napredovanja z vzdrževalnim samostojnim zdravljenjem z olaparibom v primerjavi s placebom v celotni populaciji (razmerje ogroženosti 0,35, 95 % IZ: 0,25 do 0,49, p < 0,00001).
The study of Extavia in patients with a single demyelinating event involved 487 patients, who received either Extavia or placebo for two years.
Študija zdravila Extavia pri bolnikih z enkratnim demielinizacijskim dogodkom je vključevala 487 bolnikov, ki so dve leti prejemali bodisi zdravilo Extavia ali placebo.
The study of the “Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2)” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria.
Preizkušanje delovanja irbesartana na mikroalbuminurijo pri bolnikih z visokim krvnim tlakom in diabetesom tipa 2 (IRMA 2) je pokazalo, da 300 mg irbesartana pri bolnikih z mikroalbuminurijo upočasni napredovanje v proteinurijo.
The study of the “Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2)” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria.
Preskušanje delovanja irbesartana na mikroalbuminurijo pri bolnikih z visokim krvnim tlakom z diabetesom melitusom tipa 2 (IRMA 2), je pokazalo, da pri bolnikih z mikroalbuminurijo, 300 mg irbesartana upočasni napredovanje do izražene proteinurije.
The study population consisted of approximately 48% antimuscarinic treatment naïve patients as well as approximately 52% patients previously treated with antimuscarinic medication.
Študijska populacija je obsegala pribliţno 48 % oseb, ki predhodno niso prejemale antimuskarinskih zdravil, in pribliţno 52 % oseb, predhodno ţe zdravljenih z antimuskarinskimi zdravili.
The study population consisted of generally healthy post-menopausal women between 41 to 80 years of age (mean age = 59 years), who at baseline had ≤ 5.0% superficial cells in the vaginal smear, a vaginal pH >5.0 and were required to have at least one moderate or severe VVA symptom, where patients had to choose the symptom that was the most bothersome (MBS).
Študijska populacija je bila sestavljena iz pretežno zdravih žensk po menopavzi, starih med 41 in 80 leti (povprečna starost = 59 let), ki so imele ob izhodišču ≤ 5,0% površinskih celic v brisu nožnice, pH nožnice > 5,0 in ki so imele vsaj en zmeren ali hud simptom VVA, pri čemer so bolnice izbrale simptom, ki je bil najbolj moteč (MBS, most bothersome symptom).
The study population included dogs whose tumours contained mutated or normal (‘wild-type’) c-kit receptors.
Študijska populacija je vključevala pse, katerih tumorji so imeli mutirane ali normalne („divji tip“) receptorje c-kit.
The study population included those ≥ 65 years (n=8561) and ≥ 75 years (n=2330), with normal or mild renal impairment (n=13,916) as well as moderate (n=2240) or severe (n=336) renal impairment.
Populacija v študiji je zajela bolnike, stare ≥ 65 let (n = 8.561) in ≥ 75 let (n = 2.330), z normalnim delovanjem ledvic ali blago okvaro ledvic (n = 13.916) ter tudi zmerno (n = 2.240) ali hudo (n = 336) okvaro ledvic.
The study population was 64% female, with a median age of 58 years, 4.4% had a creatinine clearance <50ml/min.
V študijskih populaciji je bilo 64 % žensk, mediana starost je bila 58 let in 4,4 % je imelo očistek kreatinina < 50 ml/min.
The study protocol shall be agreed with the CHMP prior to the start of the study and the final results (final study report) provided to the CHMP and EMA by June 2016.
Zodborom CHMP se je treba dogovoriti o protokolu študije pred začetkom študije in končne rezultate (končno poročilo o študiji) predložiti odboru CHMP ter agenciji EMA do junija leta 2016.
The study randomly assigned 460 adults who were taking two nucleoside reverse-transcriptase inhibitors and at least one PI and whose plasma HIV-1 RNA levels had been less than 200 c/ml for at least the previous six months to switch from the PI to Viramune (155 patients), efavirenz (156), or abacavir (149).
V študijo so naključno sprejeli 460 odraslih, ki so jemali dva nukleozidna zaviralca reverzne transkriptaze in najmanj enega zaviralca proteaze, in pri kateerih je bila plazemska koncentracija HIV- 1 RNA manj kot 200 kopij/ml vsaj preteklih šest mesecev pred zamenjavo zaviralca proteaze za zdravilo Viramune (155 bolnikov), efavirenz (156) ali abakavir (149).
The study results are summarized in Table 8.
Povzetek izsledkov študije je podan v preglednici 8.
The study results are summarized in Table 8.
Povzetek izsledkov študije je podan v preglednici 81.
The study showed a reduction in the number of cardiovascular events leading to hospitalisations particularly those related to atrial fibrillations.
Študija je pokazala določeno stopnjo zmanjšanja števila hospitalizacij zaradi kardiovaskularnih vzrokov, zlasti zaradi atrijske fibrilacije.
The study showed a significantly longer time to relapse in patients treated with the long-acting injectable formulation of paliperidone compared to placebo (p<0.001).
Študija je pokazala pomembno daljši čas do ponovitve simptomov pri bolnikih zdravljenih z injekcijami paliperidona s podaljšanim sproščanjem v primerjavi s placebom (p<0,001).
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p=0.025; Alzheimer´s disease cooperative study – activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
MMSE »Mini- mental State Examination«) ob vključitvi je zdravljenje z memantinom v monoterapiji pokazalo izboljšanje v primerjavi s placebom, v obdobju 6 mesečnega zdravljenja (analiza opazovanih bolnikov, lestvice Vtis sprememb na osnovi kliničnega intervjuja (CIBIC-plus oz. »Clinician's Interview-Based Impression of Change Plus Caregiver Input«): p=0,025; Vprašalnik vsakodnevnih aktivnosti (ADCS- ADLsev) (»Alzheimer's Disease Consortium Studies Activities of Daily Living-modified for severe dementia«): p=0,003; Baterije za hudo prizadetost (SIB oz. »Severe Impairment Battery«): p=0,002).
The study showed significant improvement in PFS for patients in the Kd arm over those in the Vd arm (HR: 0.53, 95% CI: 0.44, 0.65 [p value = 0.0001]) (see figure 3).
Študija je pokazala značilno boljše preživetje brez napredovanja bolezni (PFS) pri bolnikih v skupini Kd kot pri bolnikih v skupini Vd (HR: 0,53, 95 % IZ: 0,44, 0,65 [p-vrednost = 0,0001]) (glejte sliko 3).
The study showed that 15% of patients receiving 0.6 mg Signifor (12 patients out of 82) and 26% of patients receiving 0.9 mg Signifor (21 patients out of 80) had normal urine cortisol levels within six months.
Študija je pokazala, da je 15 % bolnikov, ki so prejemali zdravilo Signifor v odmerku 0,6 mg (12 bolnikov od 82), in 26 % bolnikov, ki so prejemali zdravilo Signifor v odmerku 0,9 mg (21 bolnikov od 80), imelo po šestih mesecih normalno koncentracijo kortizola v urinu.
The study showed that 42.9% (81 out of 189) of patients given Blincyto responded to treatment.
Študija je pokazala, da se je na zdravljenje z zdravilom Blincyto odzvalo okoli 42,9 % (81 od 189) bolnikov.
The study showed that a single 150 mg infusion of Ivemend was as effective as a three-day course of Emend in preventing nausea and vomiting.
V študiji je bilo dokazano, da je bila enojna 150-miligramska infuzija zdravila Ivemend pri preprečevanju slabosti in bruhanja enako učinkovita kot tridnevni cikel jemanja zdravila Emend.
The study showed that after 6 weeks of treatment average blood sugar levels decreased and clinical signs improved, for example average body weight increased.
Študija je pokazala, da so se po 6 tednih zdravljenja znižale povprečne ravni sladkorja v krvi in izboljšali klinični znaki – na primer, da se je povečala telesna masa.
The study showed that around 87% (55 out of 63) of patients responded to treatment with Imbruvica.
Pokazala pa je, da se je na zdravljenje z zdravilom Imbruvica odzvalo okoli 87 % (55 od 63) bolnikov.
The study showed that blood-phosphate levels fell on average by 0.7 mg/dl with Fexeric compared with 0.3 mg/dl with placebo.
V njej so pokazali, da so se pri zdravilu Fexeric ravni fosfatov v krvi v povprečju znižale za 0,7 mg/dl, pri placebu pa za 0,3 mg/dl.
The study showed that doubling the inhalations of each strength of salmeterol/fluticasone propionate for up to 14 days resulted in a small increase in β agonist- related adverse events (tremor - 1 patient [1%] vs 0, palpitations - 6 [3%] vs 1 [<1%], muscle cramps –6 [3%] vs 1 [<1%]) and a similar incidence of inhaled corticosteroid related adverse events (e.g. oral candidiasis - 6 [6%] vs 16 [8%], hoarseness - 2 [2%] vs 4 [2%]) compared with one inhalation twice daily.
Študija je pokazala, da je podvojitev obeh jakosti, salmeterola/flutikazonpropionata za do 14 dni povzročila majhno povečanje neželenih učinkov, povezanih z agonisti β (tremor – 1 bolnik [1 %] v primerjavi z 0, palpitacije – 6 [3 %] v primerjavi z 1 [< 1 %], mišični krči – 6 [3 %] v primerjavi z 1 [< 1 %]) in podobno pojavnost neželenih učinkov, povezanih z inhalacijo kortikosteroidov (npr. kandidazo ustne votline – 6 [6 %] v primerjavi s 16 [8 %], hripavost – 2 [2 %] v primerjavi s 4 [2 %]) v primerjavi z enim inhaliranjem dvakrat na dan.
The study showed that Izba was as effective as Travatan at reducing pressure in the eye following 2 weeks, 6 weeks and 3 months of treatment.
Pokazala je, da je po zdravljenju, ki je trajalo dva tedna, šest tednov in tri mesece, zdravilo Izba enako učinkovito pri znižanju tlaka v očesu kot zdravilo Travatan.
The study showed that Kyprolis is effective at prolonging the average length of time before the patient’s disease got worse again (progression-free survival): patients receiving Kyprolis plus lenalidomide and dexamethasone lived for an average of 26.3 months without their disease getting worse, compared with 17.6 months for patients receiving only lenalidomide and dexamethasone.
Študija je pokazala, da je zdravilo Kyprolis učinkovito pri podaljševanju povprečnega časa do ponovnega poslabšanja bolnikove bolezni (preživetje brez napredovanja): bolniki, ki so prejemali zdravilo Kyprolis skupaj z lenalidomidom in deksametazonom so povprečno živeli 26,3 meseca brez poslabšanja bolezni, bolniki, ki so prejemali samo lenalidomid in deksametazon, pa 17,6 meseca.
The study showed that Stivarga improved survival, with treated patients living for 196 days on average, compared with 151 days for those given placebo.
Študija je pokazala, da je zdravilo Stivarga podaljšalo preživetje, saj so bolniki, zdravljeni s tem zdravilom, v povprečju živeli 196 dni, bolniki, ki so prejemali placebo, pa 151 dni.
The study showed that the addition of Onivyde to the 5-fluorouracil plus leucovorin regimen prolonged patients’ lives: patients taking the three medicines together lived for around 6.1 months, compared with 4.2 months for patients taking 5-fluorouracil plus leucovorin, and 4.9 months for patients taking Onivyde alone.
Študija je pokazala, da je dodatek zdravila Onivyde k režimu 5-fluorouracil in levkovorin podaljšal življenje bolnikov: bolniki, ki so skupaj jemali tri zdravila, so živeli 6,1 meseca, v primerjavi s 4,2 meseca pri bolnikih, ki so jemali 5-fluorouracil in levkovorin, in 4,9 meseca pri bolnikih, ki so jemali samo zdravilo Onivyde.
The study was declared successful if at least one of the two co-primary endpoint was met.
Študija je bila označena za uspešno, če je bila dosežena vsaj ena od dveh sočasnih primarnih končnih točk.
The study was halted as the interim analysis (N=475) showed a low incidence of CNS events and, superior efficacy of the trastuzumab plus capecitabine arm in terms of progression-free survival and overall survival (see results of final analysis in Table 3).
Študijo so ustavili, ko je vmesna analiza (n = 475) pokazala majhno incidenco dogodkov na osrednjem živčevju in superiorno učinkovitost v kraku s kombinacijo trastuzumaba in kapecitabina glede preživetja brez napredovanja in celotnega preživetja (glejte rezultate končne analize v preglednici 3).
The study was not powered to demonstrate a difference between the vaccine and the control group for these endpoints.
Moč študije ni bila zasnovana tako, da bi dokazala razliko med cepljeno in kontrolno skupino za te opazovane dogodke.
The study was prematurely stopped after randomization of 3149 patients (placebo = 1577; dronedarone = 1572) due to the significant increase in heart failure (placebo = 33; dronedarone = 80; HR = 2.49 (1.66-3.74)]; stroke [placebo = 8; dronedarone = 17; HR = 2.14 (0.92-4.96)] and cardiovascular death [placebo = 6; dronedarone = 15; HR = 2.53 (0.98-6.53)] (see sections 4.3 and 4.4).
Študija se je končala predčasno, po randomizaciji 3.149 bolnikov (placebo = 1.577, dronedaron = 1.572), zaradi pomembnega porasta srčnega popuščanja [placebo = 33, dronedaron = 80, razmerje ogroženosti [ROg] = 2,49 (1,66-3,74)], možganske kapi [placebo = 8, dronedaron = 17, ROg = 2,14 (0,92-4,96)] in kardiovaskularnih smrti [placebo = 6, dronedaron = 15, ROg = 2,53 (0,98-6,53)] (glejte poglavji 4.3 in 4.4).
The study was primarily designed as a pharmacokinetic study (see section 5.2) and efficacy endpoints were only exploratory.
Študija je bila zasnovana predvsem kot farmakokinetična študija (glejte poglavje 5.2) in opazovani dogodki so bili zgolj raziskovalni.
The study was stopped early because of the occurrence of severe cardiovascular events (such as cardiovascular death or hospitalisation and stroke) in some patients taking Multaq.
Študija je bila ustavljena predčasno zaradi pojava resnih kardiovaskularnih dogodkov (kot so kardiovaskularna smrt ali hospitalizacija in kap) pri nekaterih bolnikih, ki so jemali zdravilo Multaq.
The study was then extended to four years.
Študija je bila kasneje podaljšana na štiri leta.
The study was unblinded based on the magnitude of clinical benefit observed and patients in the placebo group were offered treatment with ZYTIGA.
Podatke o študiji so razkrili na osnovi razsežnosti opaženih kliničnih koristi, bolnikom v skupini, ki je prejemala placebo, pa ponudili zdravljenje z zdravilom ZYTIGA.
The study went on to look at the number of bleeding episodes and rated Advate’s effectiveness in stopping bleeding on a scale from ‘none’ to ‘excellent’ in 107 patients, all of whom received Advate.
V študiji so proučevali število krvavitev in ocenjevali učinkovitost zdravila Advate pri ustavljanju krvavitve na lestvici od „neučinkovito“ do „izjemno učinkovito“ pri 107 bolnikih, ki so vsi prejemali zdravilo Advate.
The study will also provide data on pregnancies in women taking the medicine, and on healthcare professionals’ compliance with the recommendations to screen and monitor patients before and during treatment.
S študijo bodo pridobljeni tudi podatki o nosečnostih pri ženskah, ki so jemale zdravilo, in o tem, kako zdravstveni delavci upoštevajo priporočila za presejanje in spremljanje bolnikov pred in med zdravljenjem.
The study will include approximately 60 % of patients who receive vandetanib within the EU.
Študija bo vključevala približno 60 % bolnikov, ki prejemajo vandetanib znotraj EU.